Global Liquid Biopsy Market - 2024 - 2031

Market The Global Liquid Biopsy Market reached USD 4.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 12.3 billion by 2030. The Global Liquid Biopsy Market is expected to exhibit a CAGR of 15.4% during the forecast period 2024-2031. Liquid biopsy is a non-invasive medical test that detects and analyzes genetic and molecular alterations in a patient's blood or other bodily fluids.

It has gained significant attention in oncology as a promising alternative to traditional tissue biopsies.

Liquid biopsy provides valuable information about genetic mutations, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other biomarkers, allowing for diagnosing, monitoring, and personalized treatment of various types of cancers.

Furthermore, the global liquid biopsy market growth is driven by advancements such as next-generation sequencing for advanced cancer patients in liquid biopsies, an increase in the number of cancer patients, and a rise in patient preference for minimally invasive therapies.

Market Dynamics

Recent Advances in Liquid Biopsy Technologies for Cancer Biomarker Detection are Expected to Drive Liquid Biopsy Market Growth

Recent advances in liquid biopsy technologies have greatly improved the detection and analysis of cancer biomarkers. These advancements have enhanced liquid biopsy assays' sensitivity, specificity, and throughput, making them more reliable and clinically applicable.

For instance, according to the Royal Society of Chemistry Article 2022, Next-Generation Sequencing (NGS) has revolutionized liquid biopsy by enabling the comprehensive analysis of genetic alterations in circulating tumor DNA (ctDNA). It allows for the simultaneous detection of multiple genetic mutations, copy number variations, and structural variations in a single assay. NGS-based liquid biopsy panels have become increasingly accurate, sensitive, and cost-effective, facilitating the identification of targetable mutations and personalized treatment selection.

Similarly, protein-based liquid biopsy approaches aim to detect cancer-associated proteins or protein signatures in blood or other bodily fluids. Various techniques, including immunoassays, mass spectrometry, and microfluidic platforms, are used to analyze protein biomarkers in liquid biopsy samples. Protein-based liquid biopsies can detect cancer early, monitor how well the treatment works, and evaluate the presence of small amounts of remaining disease.

Emerging Liquid Biopsy Techniques for Blood-based Detection of Tumor DNA are Expected to Drive Liquid Biopsy Market Growth

Pancreatic cancer ranks as the seventh most common cause of cancer-related mortality globally. Despite a rising number of cases, the available treatments for this type of cancer are limited, leading to a bleak prognosis. Approximately 70% of patients diagnosed with pancreatic cancer succumb to the disease within one year.

For instance, a recent study published in Genome Medicine, co-led by researchers Toledo and Manuel Hidalgo, in collaboration with Nicholas McGranahan, highlights the development of a novel liquid biopsy approach called ACT-Discover—Aneuploidy in Circulating Tumor DNA (ctDNA). The study demonstrates that this technique is 30% more sensitive than existing methods when used in patients with advanced stages of pancreatic cancer.

Advancing insights into pancreatic cancer's evolution and intra-tumor heterogeneity is crucial in identifying new therapeutic targets against this disease. This technology is increasingly being employed in various cancer types to identify mutations that significantly impact drug effectiveness, thereby aiding treatment decisions. Thus, the market is expected to drive over the forecast period due to the above factors.

Challenges in the Development of Liquid Biopsy Kits are Expected to Hamper the Liquid Biopsy Market Growth

The development of liquid biopsy kits poses several challenges due to the complex nature of analyzing biomarkers in circulating fluids. One significant challenge is the need for high sensitivity and specificity in detecting rare mutations or biomarkers in low concentrations. The kit must be able to capture and analyze these biomarkers accurately, even in the presence of abundant normal DNA or other interfering substances.

Another challenge involves the selection of appropriate biomarkers for inclusion in the kit. Biomarkers should be specific to the targeted disease and have demonstrated clinical relevance. Identifying and validating such biomarkers requires extensive research and clinical trials to ensure their accuracy and utility in diagnostic or prognostic applications. Thus, owing to the above factors, the market is expected to hamper over the forecast period.

Market Segment Analysis

The Global Liquid Biopsy Market is segmented based on circulating biomarkers, products & services, applications, technology, end user, and region.

The Circulating Tumor DNA (ctDNA) Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period.

The circulating tumor DNA (ctDNA) segment accounted for the highest market stake, accounting for approximately 40.3% of the liquid biopsy market in 2022. ctDNA refers to tumor-derived DNA fragments that circulate in the bloodstream.

It contains genetic mutations and alterations specific to the tumor. Circulating Tumor DNA (ctDNA) analysis is used for non-invasive detection of tumor-specific genomic alterations, monitoring treatment response, and assessing minimal residual disease.

Moreover, Circulating Tumor DNA (ctDNA) analysis has gained significant adoption and utilization in liquid biopsy due to its accessibility, potential for real-time monitoring, and relevance to tumor-specific genomic alterations. For instance, in a patient with advanced lung cancer, ctDNA analysis is performed before initiating targeted therapy.

The ctDNA analysis identifies specific genetic mutations associated with the tumor, such as EGFR or ALK mutations. This information helps determine the most appropriate targeted therapy for the patient.

During treatment, regular monitoring of ctDNA levels allows for assessing treatment response. A decrease in ctDNA levels indicates a positive response to therapy, while an increase may suggest treatment resistance or disease progression.

This real-time monitoring enables timely adjustments in treatment plans, such as switching to alternative therapies or combining treatment modalities. Thus, the market segment is expected to hold the largest market share over the forecast period due to the above factors.

Market Geographical Share

North America Holds a Dominant Position in the Global Liquid Biopsy Market.

North America is estimated to hold around 38.9% of the total market share throughout the forecast period. Owing to the increasing prevalence of cancer, rapid technological advancements, growing government initiatives, and recent FDA approvals for liquid biopsy tests in the region are the factors expected to hold the largest market share over the forecast period.

For instance, according to the American Cancer Society's journal CA: A Cancer Journal for Clinicians, cancer remains the second leading cause of death in the United States, following heart disease. In 2023, it is estimated that there will be approximately 1.9 million new cancer cases (equivalent to around 5,370 cases per day) and 609,820 cancer-related deaths (about 1,670 deaths per day) in the US.

Therefore, liquid biopsy provides a non-invasive alternative to traditional tissue biopsies for cancer diagnosis and monitoring. As the prevalence of cancer rises, the demand for non-invasive diagnostic methods increases. Liquid biopsy offers a less invasive and more convenient option for patients, leading to its greater adoption and utilization in clinical practice. Thus, the North American region is expected to hold the largest market share over the forecast period due to the above factors.

Market Players

The major global players in the market include Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Exosome Sciences Inc., Grail Inc, Guardant Health, Thermo Fisher Scientific Inc., Inivata Ltd, Illumina Inc, LungLife AI Inc, and Qiagen NV among others.

COVID-19 Impact on Market

The COVID-19 pandemic had a significant impact on the liquid biopsy market. During the pandemic, there has been a decrease in routine healthcare visits, including cancer screenings and diagnostic procedures. As a result, the demand for liquid biopsy tests may have been affected, as these tests are often used as non-invasive alternatives to traditional tissue biopsies. Reduced patient visits and diagnostic testing have likely resulted in a decline in the overall adoption and utilization of liquid biopsy technologies.

Moreover, many ongoing clinical trials related to liquid biopsy research and development have experienced delays or disruptions due to the pandemic. Restrictions on patient recruitment, limited access to healthcare facilities, and prioritization of resources for COVID-19 management have resulted in the postponement or alteration of clinical trial timelines. This delay in research activities can impact the introduction of new liquid biopsy technologies and products to the market.

As the pandemic situation evolves and healthcare systems adapt, the liquid biopsy market is expected to recover and continue its growth trajectory, driven by advancements in technology, research, and the increasing demand for personalized and non-invasive cancer diagnostics.

Russia Ukraine Conflict Analysis

The Russian-Ukraine war has had implications for various sectors, including the healthcare industry and potentially the liquid biopsy market. The war has caused substantial interruptions in impacted regions' healthcare infrastructure, particularly Ukraine. Damage to medical facilities, medical supply shortages, and the relocation of healthcare staff can all interrupt the routine operation of healthcare systems.

Moreover, the war and its economic consequences can bring about shifts in healthcare expenditure and priorities. With limited budgets and a need to allocate resources to war-related efforts and post-conflict rebuilding, there may be reduced investment in healthcare infrastructure, research, and development. Consequently, the progress and widespread adoption of advanced technologies such as liquid biopsy could be impeded in the regions affected by the conflict.

The ongoing conflict can pose obstacles to research and development endeavors in the affected regions. Constraints on funding and resources, along with an unsettled research environment, can slow down the progress of innovation and scientific breakthroughs concerning liquid biopsy technologies. Additionally, collaborating and exchanging knowledge and expertise with international partners may face challenges amidst the conflict.

By Circulating Biomarker
• Circulating Tumor Cells
• Circulating Tumor DNA (ctDNA)
• Cell-free DNA (cfDNA)
• Extracellular Vesicles
• Others

By Product & Services
• Kits & Reagents
• Instruments
• Services

By Application
• Cancer Applications
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Liver Cancer
Other
• Non-Cancer Applications
Non-Invasive Prenatal Testing (NIPT)
Organ Transplantations
Infectious Disease Testing

By Technology
• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

By End User
• Hospitals and Physician Laboratories
• Research Centers
• Others

By Region
• North America
The U.S.
Canada
Mexico
• Europe
Germany
The U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On April 18, 2023, Qiagen, a global provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research, announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for next-generation sequencing (NGS) in less than eight hours.
• On April 18, 2023, Stilla Technologies announced the availability of 20 new digital PCR assays, optimized for its Crystal Digital PCR platform, the naica system, to be utilized for the detection of circulating tumor DNA (ctDNA) from liquid biopsy samples.

Produced by distributor and technology partner ApexBio, these digital PCR kits are designed for the absolute quantitation of nucleic acids from genetic mutations found across a widespread range of oncological indications.
• On November 30, 2022, Thermo Fisher Scientific released a slew of dPCR Liquid Biopsy assays for their Applied Biosystems Absolute Q dPCR system and a custom design tool to help with cancer research.

The business announced the availability of more than 50 Absolute Q Liquid Biopsy Assays for use on the fully integrated digital PCR system, which is meant to produce results in 90 minutes with minimal hands-on time.

Why Purchase the Report?
• To visualize the Global Liquid Biopsy Market segmentation based on the circulating biomarker, product & services, application, technology, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous liquid biopsy market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Liquid Biopsy Market Report Would Provide Approximately 77 Tables, 77 Figures And 195 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies